GLP-1 Receptor Agonists and Sleep Architecture: SURMOUNT-OSA Data, Upper Airway Adiposity Reduction, SWS-Testosterone Coupling, and CPAP Titration Protocol

Obstructive sleep apnea pathophysiology in men centers on pharyngeal collapsibility — quantified as critical closing pressure (Pcrit), the luminal pressure at which the pharynx collapses during inspiration. Excess parapharyngeal and perilingual fat deposits mechanically reduce pharyngeal cross-sectional area and increase airway compliance, lowering the Pcrit threshold (making collapse more likely) and requiring higher pharyngeal dilator muscle tone to maintain patency. MRI volumetric studies demonstrate that parapharyngeal fat pads correlate more strongly with AHI than overall BMI, explaining why regional fat distribution predicts OSA severity better than generalized obesity. GLP-1R agonists target these depots through preferential visceral and peripharyngeal adipose mobilization — distinct from subcutaneous fat, visceral and peripharyngeal adipocytes have higher GLP-1R expression density and greater cAMP-mediated lipolytic responsiveness. The SURMOUNT-OSA magnitude of AHI reduction (-29.3 events/hr at 15mg) substantially exceeds what weight loss alone would predict from epidemiological data (typically 3% AHI reduction per 1% weight loss), suggesting additional mechanisms: reduced rostral fluid shift during recumbency as lower leg edema resolves (contributing to upper airway narrowing in obese patients), and potential direct GLP-1R effects on pharyngeal dilator muscle tone via brainstem nucleus tractus solitarius projections.

Approximately 70% of nocturnal testosterone secretion occurs during SWS (N3), driven by hypothalamic GnRH pulsatility that is itself synchronized to delta-wave EEG activity via GABAergic interneuron modulation. Each apnea event generates transient hypoxemia (SaO2 nadir typically 80-88% in moderate-severe OSA) and hypercapnia, activating peripheral chemoreceptors and the sympatho-adrenal axis: cortisol rises 15-40 nmol/L per event, norepinephrine surges, and the arousal response prevents SWS consolidation. Chronically disrupted SWS reduces hypothalamic GnRH pulse amplitude and frequency — the same mechanism by which chronic psychological stress suppresses the HPG axis. Studies using polysomnography plus hourly testosterone sampling in men with OSA demonstrate that SWS percentage predicts morning testosterone independent of age and BMI: each 10% reduction in SWS corresponds to approximately 40-50 ng/dL reduction in morning testosterone (Luboshitzky et al., JCEM). CPAP therapy partially restores SWS — but CPAP compliance (typically 50-60% for ≥4 hours per night) limits the hormonal benefit. Full OSA resolution (AHI <5/hr) as achieved in 51% of SURMOUNT-OSA participants would be expected to produce complete SWS architecture restoration, yielding testosterone recovery superior to CPAP in the compliance-limited population.

Gastroesophageal reflux disease (GERD) in overweight men is mechanistically relevant to sleep architecture through two pathways. First, nocturnal acid reflux events produce micro-arousals detectable on polysomnography — inadequate to reach full wakefulness but sufficient to fragment SWS continuity. Second, GERD is associated with nighttime cortisol elevation via vagal nerve stimulation of the HPA axis and inflammatory cytokine induction. GLP-1R agonists improve GERD through coordinated mechanical effects: reduced gastric acid secretion volume (GLP-1R on parietal cells suppresses acid secretion via cAMP/PKA-mediated H+/K+-ATPase activity reduction), delayed gastric emptying (prolonged lower esophageal sphincter contact time), and reduced intragastric pressure from smaller meal volumes and reduced adipose visceral compression of the stomach. The lower esophageal sphincter (LES) tone improvement is likely secondary to reduced transient LES relaxation frequency as intra-abdominal pressure falls with visceral adipose reduction. GLP-1's suppression of hypothalamic PVN CRH release — the upstream initiator of the HPA stress cascade — reduces nocturnal cortisol independently of airway effects. This dual action (airway restoration + direct CRH suppression) makes GLP-1's effect on nocturnal hormonal milieu additive rather than redundant to CPAP.

CPAP pressure settings are derived from polysomnographic titration at a fixed body weight and airway geometry. As weight decreases on GLP-1 therapy, pharyngeal cross-sectional area increases, reducing the critical closing pressure — the same CPAP pressure that was optimal at baseline may now exceed the required therapeutic level. Suprapherapeutic CPAP pressure generates aerophagia (air swallowing via the upper esophageal sphincter, which cannot tonically resist high inspiratory pressures during sleep), producing morning bloating, belching, and occasionally dangerous gas distension. It also increases the propensity for central apneas via the Hering-Breuer reflex, creating a complex central-obstructive mixed picture that worsens sleep quality metrics. Clinical protocol recommendation: auto-titrating CPAP (APAP) with a narrowed pressure range is preferable during active weight loss, as the device adjusts pressure in real time based on detected airway resistance. If on fixed-pressure CPAP, schedule pressure re-titration (split-night study or at-home auto-titration) at 10-15% body weight reduction milestones, or approximately every 20 lbs. If AHI on home auto-CPAP data download falls below 5 on ≥3 consecutive weeks, formal OSA re-evaluation (full-night PSG or home sleep study) is warranted to assess for resolution and CPAP discontinuation eligibility. Magnesium glycinate 400mg and phosphatidylserine 400mg in the Helian Deep Rest PM stack complement GLP-1's cortisol-suppressing effects: magnesium via GABA-A potentiation reduces sleep-onset cortisol, and PS specifically attenuates HPA axis response to the residual micro-stress events that may persist even after OSA resolution.